Literature DB >> 19189103

TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008.

Wolfgang Uckert1, Ton N M Schumacher.   

Abstract

The genetic introduction of T cell receptor genes into T cells has been developed over the past decade as a strategy to induce defined antigen-specific T cell immunity. With the potential value of TCR gene therapy well-established in murine models and the feasibility of infusion of TCR-modified autologous T cells shown in a first phase I trial, the next key step will be to transform TCR gene transfer from an experimental technique into a robust clinical strategy. In this review, we discuss the different properties of the TCR transgene and transgene cassette that can strongly affect both the efficacy and the safety of TCR gene transfer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19189103     DOI: 10.1007/s00262-008-0649-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

1.  Protective capacity of virus-specific T cell receptor-transduced CD8 T cells in vivo.

Authors:  Katja Mueller; Anne von Mässenhausen; Ulrike Aichele; Lilian Stärck; Matthias Leisegang; Wolfgang Uckert; Hanspeter Pircher
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

Review 2.  Designing T cells for cancer immunotherapy.

Authors:  Leslie E Huye; Gianpietro Dotti
Journal:  Discov Med       Date:  2010-04       Impact factor: 2.970

Review 3.  NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

Authors:  Edwin P Alyea; Daniel J DeAngelo; Jeffrey Moldrem; John M Pagel; Donna Przepiorka; Michel Sadelin; James W Young; Sergio Giralt; Michael Bishop; Stan Riddell
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-24       Impact factor: 5.742

4.  TCR mispairing in genetically modified T cells was detected by fluorescence resonance energy transfer.

Authors:  Hongwei Shao; Wenfeng Zhang; Qinglian Hu; Fenglin Wu; Han Shen; Shulin Huang
Journal:  Mol Biol Rep       Date:  2010-04-06       Impact factor: 2.316

5.  Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes.

Authors:  Peter Meyerhuber; Heinke Conrad; Lilian Stärck; Matthias Leisegang; Dirk H Busch; Wolfgang Uckert; Helga Bernhard
Journal:  J Mol Med (Berl)       Date:  2010-08-11       Impact factor: 4.599

6.  Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.

Authors:  Shigui Zhu; Benoit J Van den Eynde; Pierre G Coulie; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

Review 7.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

Review 8.  Potential of human γδ T cells for immunotherapy of osteosarcoma.

Authors:  Zhaoxu Li
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

Review 9.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

10.  Sarcoma Tumor Microenvironment.

Authors:  Panagiotis Tsagozis; Jordi Gonzalez-Molina; Anna-Maria Georgoudaki; Kaisa Lehti; Joseph Carlson; Andreas Lundqvist; Felix Haglund; Monika Ehnman
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.